

Form PTO-1449 Docket Number D2935-CON2 Application Number 09/845,512 INFORMATION DISCLOSURE CITATION Applicant Aoki et al. IN AN APPLICATION Filing Date 4/30/01 (Use several sheets if necessary) **U. S. PATENT DOCUMENTS** DOCUMENT NUMBER CLASS SUBCLASS FXAMIN DATE NAME FILING DATE IF APPROPRIATE ER INITIAL RUI 2,373,454 4/1945 Bunny et al. 167 78 2,719,102 9/1955 **Baldwin** 167 78 3,132,995 5/1964 Berger et al. 167 78 4,713,240 12/1987 Wilkins et al. 424 92 4,932,936 6/1990 Dykstra et al. 604 51 5,055,291 10/1991 Lam et al. 424 85.91 10/1991 424 427 5,055,302 Laties et al. 10/1991 **Borodic** 604 5,053,005 51 Borodic 51 5,183,462 2/1993 604 3/29/1994 2 5,298,019 • **Borodic** 3/28/1995 5,401,243 Borodic 5,696,077 12/9/97 Johnson et al. not pulled 09/812 113 17006CON1 3/15/2001 Aoki et al. articles 17006CH 8/20/2000 -09/636,50T -Aoki-et al. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER COUNTRY CLASS SUBCLASS TRANSLATION DATE YES ACH WO 93/05,800 wo 4/1993 WO 94/00,481 1/6/1994 WO Res WO 95/17904 * WO 7/6/1995 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) CCH Schantz et al. (1992) Microbiological Review, 56(1):pp 80-99. aa Hambleton (1992) Journal of Neurology, 239(1):16-20. ab Ral ac Ludlow et al. (1992) The New England Journal of Medicine 326(5):349-350. ad Greene et al. (1993) Movement Disorders 8(4): 479-483. Jankovic et al. (1991) The New England Journal of Medicine 324(17):1186-1194. ae Siatkowski et al. (1993) Opthamology 100:1861-1866. af Simpson et al. (1981) Pharmacol. Rev. 33(3):155-188. ag Blasl et al. (1993) Nature 365:160-163. ah EXAMINER **DATE CONSIDERED**

EXAMINER: initial if cliation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449 Docket Number D2935-CON2 Application Number 09/845,512 INFORMATION DISCLOSURE CITATION Applicant Aoki et al. IN AN APPLICATION 1647 Filing Date 4/30/01 Group Art Unit 1646 (Use several sheets if necessary) **U. S. PATENT DOCUMENTS** EXAMIN DOCUMENT NUMBER DATE CLASS SUBCLASS FILING DATE IF APPROPRIATE INITIAL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) ai Dasgupta, Botulinum Neurotoxin and Tetanus Toxin; Edited by Simpson, Lance; 53-67(1989) Academic Plens Inc aj Gjerstad et al. (1991) Tidsskr Nor Laegeforen nr 111:2637-9. (Translation submitted). ak Moyer et al. (1994) Therapy With Botulinum Toxin; Edited by Jankovic et al.; 71-85. al RCH Moyer et al. (1993) Botulinum and Tetanus Neurotoxins; Edited by Dasgupta; 655-656 Penum Ress, Nu. 1 am Poewe et al. (1994) Therapy With Botulinum Toxin; Edited by Jankovic et al.; 267-278. an Schantz et al. (1992) American Society for Microbiology 56:80-99. ao ap Scott et al. (1988) Movement Disorders 3(4):333-335. Simpson (1992) Journal of Voice 6(4):358-364. aq Tsui et al. (1985) Canadian Journal of Neurological Sciences 12(4):314-316. ar Tsui et al. (1995) Neurology 45(11):2109-2110. as Tsui et al. (1987) Le Journal Canadien Des Sciences Neurologiques 14(3)Supp:533-535. at Athena files US and Canadian Investigational New Drugs (INDs); Scrip (1992); No. 1724, p.29. ลน Athena Makes a Wise Move (1992) Medical Advertising News; p. 4. av Athena Outlines Business Strategy (1992) Marketletter, p N/A.

Breggin (1992) Controversial Issues in Mental Health; Edited by Stuart A. Kirk et al. p.\$46-159, Allynama Bacon, Needham Height aw ax of Botulinum Toxin; with a web address http://www.text.nlm.nih.gov/nih/edc/www/83txt.html-6 pages out of 257 entitled U.S. Food and Drug Administration; List of Orphan Designations and Approvals; with a web address http://www.fda.gov/orphan/designat/list.htm (1984-1999). Alexander (1999) Clinical Psychopharmacology Sommar; 1-18. bb Aoki (1999) European Journal of Neurology; 6(Suppl. 4):S3-S10. Aoki et al. (1999) Neurology 52(6 Suppl. 2):A521-2 P06.109. bc Brashear et al. (1999) Neurology 53:1439-1446. bd be Brin et al. (1999) Neurology 53:1431-1438. bf Carruthers et al. (2000) Dermatol Surg. 26(3):174-176. **EXAMINER DATE CONSIDERED** 6/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

0	IPE CLE
. OCT	0 9 2001
(3	(6)

	ł	
Docket Number D2935-CON2	Application Number	09/845,512

	70.	OCT 0 9 2001		Sheet :	LECH CENTER 1800/550	OCT 1 2 2001	i
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		& TRADEMART	Docket Number D2935-CON2	Application Number 09/845,512	—	<u> </u>	Ĺ
		IATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Aoki et al.	1647		2 2	Ļ
		(Use several sheets if necessary)	Filing Date 4/30/01	Group Art Unit 1646		001	Ţ
01/	Γ.	OTHER DOCUMENTS (Including A		ges, Etc.)	-\$		
I-CH	bg	Ishikawa et al. (2000) Jpn J Ophthalmol 44			_		
No dal		Hatheway; Bacterial Sources of Clostridial		nodate :			
RC14	bi L:	Li et al. (1998) Biochimica et Biophysica A					
	bj bk	Singh (1999) J. Toxicol-Toxin Reviews; 18 Singh et al. (1995) Journal of Protein Chem	· · · · · · · · · · · · · · · · · · ·		-		
	ы	Singh et al. (1996) Toxicon 34(7):737-742.			\dashv		
	bm	Spanoyannis et al. (1998) Dev Med Child N			\dashv		
hypalini		Dystonia, Inc. computer printout; What is S		2 (downloaded and printed			
hupahlink		Dystenia Foundation computer printout; Sp	asmadic Tarticallis; nages 1-3: (late	ct undeted 8/6/09			
COLOR	NO.	Dystonia i oundation computer primous, ap	womano - or meeting, purgetties, quant	er apaated 0.0/70).			

			-				
				State of the state	_		
				· · · · · · · · · · · · · · · · · · ·	_		
					4		
					4		
_							
					\dashv		
EXAMINE			DATE CONSIDERED		-		
-AMINE	(, ,	Vayes	6/22/04				
1	v /	/ U- 1/	W/22/04		11		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.